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Introduction {#s1}
============

Maternal smoking during pregnancy is one of the most prevalent and modifiable risk factors affecting newborn health ([@c15]). In the United States, $> 8\%$ of women smoke during pregnancy, with the highest rates occurring during the first trimester ([@c15]). Prenatal exposure to tobacco smoke has been associated with adverse health outcomes for offspring, including overall fetal and infant mortality ([@c36]), preterm birth ([@c52]), altered fetal thyroid function ([@c45]; [@c53]), obesity ([@c6]), childhood cancers ([@c32]), behavioral and cognitive effects ([@c13]; [@c28]; [@c29]), and asthma ([@c24]).

As epigenetic modifications represent organismal flexibility in adapting to environmental stressors, epigenetic dysregulation is one hypothesized mechanism by which exposure to tobacco smoke *in utero* may contribute to such a diverse array of adverse health outcomes later in life. Consistent with this, a growing body of evidence, including a meta-analysis of results from 13 cohorts ([@c34]), suggests that maternal smoking during pregnancy alters newborn DNA methylation patterns, and some of these effects have been shown to persist throughout childhood ([@c4]; [@c10]; [@c41]; [@c49]), and even into adolescence ([@c41]) and adulthood ([@c22]; [@c49]). However, most studies evaluating associations between maternal smoking during pregnancy and DNA methylation have focused on a handful of candidate genes or utilized methylation arrays, which cover a small fraction ($< 5\%$) of CpG sites in the human genome, largely selected from promoter regions. A recent study, using whole-genome bisulfite sequencing (WGBS), observed that maternal smoking during pregnancy largely impacts DNA methylation levels within enhancer regions ([@c5]), which until recently were underrepresented on methylation arrays. Thus, the most profound effects of maternal smoking during pregnancy may occur at distal regulatory regions, which have been largely unevaluated.

Another important limitation of previous studies is that most have measured DNA methylation in whole blood or total leukocyte samples, which consist of a mixture of different cell types, each with its own distinct DNA methylation profile. Findings from these studies therefore represent methylation differences averaged across multiple cell types. These studies also may have been susceptible to confounding by cell type heterogeneity. Although the importance of accounting for major cell types has been emphasized by two recent studies, which observed differential effects of maternal smoking during pregnancy on DNA methylation in leukocyte subtypes ([@c4]; [@c55]), studies evaluating the influence of maternal smoking during pregnancy on DNA methylation patterns within specific cell types are still generally lacking. Additionally, most previous studies of prenatal tobacco smoke exposure and DNA methylation have focused on predominately Caucasian populations (e.g., [@c35]; [@c39]; [@c44]; [@c49]). Much less is known about the impact of *in utero* tobacco smoke exposure on newborn DNA methylation patterns in Hispanic populations.

The objective of the current study was therefore to investigate the impact of maternal smoking during pregnancy on the newborn methylome, using WGBS, within sorted cord blood $\text{CD}4^{+}$ cells collected from a subset of Hispanic white participants enrolled in the Maternal and Child Health Study (MACHS), a Los Angeles birth cohort that was designed to identify early-life risk factors for adverse metabolic and respiratory outcomes in childhood. On average, $\text{CD}4^{+}$ cells comprise 10--16% of white blood cells in cord blood. They are essential for host defense, as they coordinate immune responses to infections and malignancies by recruiting and activating other immune cells ([@c57]). They were selected for the current study because they are accessible in healthy newborns and relevant to tobacco smoke toxicity, as they have also been implicated in the pathogenesis of airway inflammation and asthma ([@c2]; [@c42]; [@c43]).

Methods {#s2}
=======

Maternal and Child Health Study {#s2.1}
-------------------------------

MACHS is a birth cohort in Los Angeles. Beginning in 2012, MACHS participants were recruited from the labor and delivery ward of the Los Angeles County and University of Southern California Medical Center, which serves a predominately low-income Hispanic population. Women were excluded from the study if they were HIV positive, currently incarcerated, or $< 18\,\text{years}$ old. Women were also excluded if they had a multiple pregnancy or a physical, mental, or cognitive disability that would preclude their participation in the study. Written informed consent was obtained from all participants in accordance with the Health Sciences Institutional Review Board of the University of Southern California.

For the current study, 10 infants with exposure to maternal smoking *in utero* and 10 unexposed infants born to Hispanic white women were identified in MACHS and matched on fetal gestational age, maternal diabetes status, maternal prepregnancy body mass index (BMI), and maternal age ([Table 1](#t1){ref-type="table"}).

###### 

Maternal and newborn characteristics of Maternal and Child Health Study (MACHS) participants by exposure group.

Table 1 lists participant characteristics in the first column. The corresponding values for the tobacco smoke exposed and unexposed newborns for the subset of MACHS participants with WGBS data; p-values for differences between the exposure groups; and values for all participants in the larger MACHS study population are listed in the other columns.

                                      WGBS subset                                        Larger MACHS study population          
  ----------------------------------- -------------------------------------------------- ------------------------------- ------ ------------------------------------------------
  Matched characteristics                                                                                                       
   Age, years                         $25 \pm 6$                                         $27 \pm 8$                      0.62   $27 \pm 6$[^*b*^](#TF3){ref-type="table-fn"}
   Prepregnancy BMI, ${{kg}/m}^{2}$   $29.6 \pm 5.9$[^*c*^](#TF4){ref-type="table-fn"}   $28.8 \pm 5.6$                  1      $28.7 \pm 8$[^*d*^](#TF5){ref-type="table-fn"}
   Prepregnancy diabetes              0 (0)                                              0 (0)                           1      13 (5.6%)[^*e*^](#TF6){ref-type="table-fn"}
   Gestational age, weeks             $38 \pm 2$                                         $38 \pm 2$                      0.62   $39 \pm 2$[^*f*^](#TF7){ref-type="table-fn"}
   Preterm                            2 (20)                                             2 (20)                          1      44 (19)
  Adjustment characteristics                                                                                                    
   Baby's sex, male                   6 (60)                                             7 (70)                          1      115 (50)
   Mother worked during pregnancy     7 (70)                                             6 (60)                          1      101 (44)

Note: BMI, body mass index; MACHS, Maternal and Child Health Study; SD, standard deviation; WGBS, whole-genome bisulfite sequencing.

*p*-value is from Wilcoxon rank-sum test (continuous variables), chi-square test (categorical variables with $> 5$ counts per cell), or Fisher's exact test (categorical variables with $< 5$ counts per cell), comparing participants in the maternal tobacco smoke exposed group with the unexposed group.

Maternal age information available for $n = 228$ participants.

One participant from the maternal tobacco smoke exposed group was missing information on maternal prepregnancy BMI.

Maternal prepregnancy BMI available for $n = 179$ participants.

Maternal prepregnancy BMI available for $n = 232$ participants.

Gestational age information available for $n = 226$ participants.

Assessing Maternal Smoking during Pregnancy {#s2.2}
-------------------------------------------

Maternal smoking during pregnancy was assessed by an interview-administered questionnaire, which was provided in either English or Spanish, depending on the primary language of the participant. Of the 10 mothers who smoked during pregnancy who were selected for this study, nine reported that they stopped smoking soon after learning that they were pregnant or at some point during the first trimester, and one reported that she had stopped smoking during the third trimester. The 10 women who did not smoke during pregnancy were lifetime nonsmokers. Although cigarette smoke exposure from other sources was not directly considered for this analysis, four of the women who reported smoking during pregnancy, and one woman who reported being a lifetime nonsmoker, shared a residence with a cigarette smoker.

Other Maternal and Newborn Characteristics {#s2.3}
------------------------------------------

Prepregnancy BMI was calculated based on prepregnancy height and weight values obtained from maternal medical records. Gestational age and baby's sex were acquired from pediatric medical records. Maternal age, prepregnancy diabetes status, and working status during pregnancy were determined by an interview-administered questionnaire, provided in the primary language of the participants (English or Spanish) at the time of delivery.

Cord Blood Collection, Cell Sorting, and DNA Isolation {#s2.4}
------------------------------------------------------

Cord blood samples were drained into collection containers by hospital providers and then transferred by standard syringe into EDTA tubes BD Biosciences (Catalog Number: BD-366643). Samples were stored at room temperature until they were transported to the molecular biology laboratory at the Southern California Environmental Health Sciences Center, where they were processed. The median time from cord blood collection to sample processing was 14 h, which did not differ by exposure group ($p_{\text{Wilcoxon}} = 0.80$).

Peripheral blood mononuclear cells (PBMCs) were isolated by treating 5--10 mL of whole blood with Human Granulocyte Depletion Cocktail (STEMCELL Technologies) for 20 min. The blood was diluted with an equal volume of EasySep™ Buffer (STEMCELL Technologies), which was mixed and overlaid into a 50-mL SepMate™ tube (STEMCELL Technologies) filled with 15 mL Lymphoprep™ (STEMCELL Technologies). The tube was centrifuged at $1,200 \times g$ for 10 min, and the PBMC layer was transferred into a 50-mL centrifuge tube using a transfer pipette. Cells were washed with 20 mL of EasySep™ Buffer and centrifuged for 8 min at $300 \times g$. The cell pellet was resuspended in 2 mL of EasySep™ Buffer, then transferred into a 14-mL polystyrene tube. $\text{CD}14^{+}$ monocyte cells and $\text{CD}4^{+}$ T cells were then separated using the EasySep™ Human CD14 Selection Kit (STEMCELL Technologies), followed by the EasySep™ Human CD4 Selection Kit (STEMCELL Technologies), according to manufacturer protocols. Lysed buffy coat, $\text{CD}14^{+}$, and $\text{CD}4^{+}$ cells were suspended in Qiagen $\text{RLT} + /2\text{-mecaptoethanol}$ and stored at $- 20{^\circ}C$ until DNA extraction. This kit typically yields 97.4--99.5% $\text{CD}4^{+}$ cell content.

DNA was isolated from sorted $\text{CD}4^{+}$ cells using the Qiagen All Prep DNA/RNA/miRNA kit (80224; Qiagen), according to the manufacturer's instructions. A260:A280 ratios were determined by nanodrop and ranged between 1.80 and 1.94.

Whole-Genome Bisulfite Sequencing {#s2.5}
---------------------------------

Five hundred nanograms of DNA were shipped overnight on dry ice to BGI. Library preparation consisted of: *a*) sonication of the DNA to create 100--300 base pair fragments; *b*) DNA end repair, addition of 3' adenine overhangs, and ligation of methylated sequencing adaptors; *c*) bisulfite treatment using the EZ DNA Methylation-Gold Kit™ (Zymo Research); and *d*) desalting, size selection, polymerase chain reaction (PCR) amplification (10 cycles), and an additional round of size selection. Library fragment size (250--300 base pairs) was verified by a 2100 Bioanalyzer (Agilent). Library concentration ($> 5.39\,\text{nM}$) was verified by quantitative real-time PCR. 150 base pair, paired-end WGBS was performed by BGI, using Illumina's HiSeq 4000 System. Samples were multiplexed, and three samples were run per lane. The raw and processed WGBS data that were generated and analyzed for the current study are publicly available in Gene Expression Omnibus (GEO) (accession: GSE109212) [@c61]; [@c59].

Read Alignment {#s2.6}
--------------

Trim Galore! (version 0.4.2, Babraham Bioinformatics) was used to assess read quality and to remove adapters from raw sequencing reads and conduct quality trimming, using the default Phred score cutoff of 20. Trimmed reads were mapped to human assembly GRCh37, using the Wildcard ALignment Tool ([@c12]). Eighty-four percent of the trimmed reads were mapped, and 93% of these were uniquely mapped. The MethPipe package (version 3.4.2) was used to remove duplicate reads and to calculate average CpG methylation levels and bisulfite conversion rates ([@c54]). The median percent duplication rate was 19%. The median coverage for a CpG site was $6.5 \times$. Mapping rates, percent duplication rates, and coverage were similar in the exposed and unexposed groups. Median bisulfite conversion rates were 0.99 in both groups.

Statistical Analysis {#s2.7}
--------------------

Differentially methylated CpG sites were identified using Regression Analysis of Differential Methylation (RADMeth) ([@c19]), which utilizes beta-binomial regression and is part of the MethPipe pipeline ([@c54]). We selected this method because it accounts for within-group variation in methylation and is therefore more appropriate for population studies, and has been shown to perform well on low-coverage data ([@c19]). The code for this method is publicly available (<https://github.com/smithlabcode/methpipe>). Although there were no significant differences between the exposed and unexposed groups for any measured maternal or newborn characteristics, there was one fewer male baby and one more mother who worked during pregnancy in the tobacco smoke--exposed group ([Table 1](#t1){ref-type="table"}). We therefore included baby's sex and maternal working status as covariates in regression models. The RADMeth program calculates three sets of *p*-values: *a*) raw *p*-values; *b*) *p*-values adjusted for their correlations with proximal CpGs (based on a 200-base pair window), which increases the statistical power to detect differential methylation, even at low-coverage sites, as described previously ([@c19]); and *c*) neighbor-adjusted *p*-values that are additionally corrected for multiple testing based on the Benjamini-Hochberg method for controlling the false discovery rate (FDR) ([@c7]) (hereafter referred to as $p_{\text{FDR}}$). The genomic inflation factor ($\lambda$) was calculated from the raw *p*-values. CpG sites with a $p_{\text{FDR}} < 0.05$ were considered differentially methylated. Differentially methylated regions (DMRs) were also called using RADmeth, which joins neighboring CpG sites that were identified as differentially methylated ($p_{\text{FDR}} < 0.05$). Resulting DMRs were filtered for those containing a minimum of at least three CpG sites with both a raw and FDR-adjusted $p < 0.05$ to capture potential methylation differences at regulatory regions that are CpG poor (e.g., enhancers) in addition to those that are CpG rich (e.g., promoters) ([@c33]). Since MethPipe does not systematically check for outliers, we visually inspected for outliers in a subset of loci by plotting the raw methylation values for individual participants separately by exposure group. Given the low coverage of our data, we attempted to run a sensitivity analysis restricting to the 1.4 million CpGs in our dataset that had an average coverage $\geq 10 \times$. However, the RADMeth program was unable to run on this restricted set of CpGs, likely because the data were too sparse. We were therefore also unable to run the subsequent DMR identification step for this restricted set of data.

Annotation of genomic regions was conducted using the Goldmine package in R (version 3.5.0, R Project) ([@c8]). Significant enrichment of DMRs at genomic regions of interest was determined using Fisher's exact test. The drawGenomePool() function in the Goldmine package was used to create a length-matched pool of background sequences from GRCh37 that was $100 \times$ the size of the query and did not *a*) overlap sequences in our query; or *b*) extend off chromosome ends or over assembly gaps ([@c8]). Additionally, overlap between DMRs and FANTOM5 enhancers was examined ([@c3]). We used a three-pronged approach and evaluated overlap with *a*) all known enhancers, *b*) enhancers expressed in T cells, and *c*) enhancers expressed ubiquitously across tissue types. Additionally, we examined overlap between DMRs and $\text{CD}4^{+}$ DNase-sensitive regions and transcription factor binding sites. Coordinates for $\text{CD}4^{+}$ DNase-sensitive regions were determined by merging three DNase-seq datasets for adult $\text{CD}4^{+}$ T cells, acquired from the ENCODE Experimental Data Matrix (file accession numbers: ENCFF569GSL, ENCFF235AEA, and ENCFF907KBL, generated in the lab of John Stamatoyannopoulos, University of Washington) ([@c21]). Overlapping features were merged using version 2.26.0, BEDTools ([@c48]). Coordinates for $\text{CD}4^{+}$ transcription factor binding sites were acquired from ReMap ([@c26]). Additionally, CTCF $\text{CD}4^{+}$ binding site coordinates were obtained from GEO (accession number GSE12889) ([@c14]) and converted to GRCh37 using the University of California Santa Cruz Genome Browser liftOver tool ([@c27]). Gene set enrichment analyses for PANTHER pathways ([@c46]) and gene ontology (GO) terms ([@c23]) were conducted for all genes directly overlapping DMRs using the enrichR software ([@c38]). Predicted targets of microRNAs (miRNAs) overlapping DMRs were identified using three different software programs: TargetScanHuman7.2 ([@c1]), miRWalk 2.0 ([@c20]), and version 5.0, DIANA-microT-CDS tools ([@c47]). The intersection of predicted target genes identified by all three tools was then evaluated in downstream analyses. Potential enrichment of predicted target genes within PANTHER pathways ([@c46]) and GO terms ([@c23]) associated with predicted targets were determined using enrichR ([@c38]).

To identify single-nucleotide polymorphisms (SNPs) that might impact CpGs of interest, coordinates were obtained for all SNPs identified by the 1000 Genomes Project. Since the MXL population, which represents Mexican American individuals from the Los Angeles area, is the most similar to MACHS, we identified SNPs that are common (minor allele $\text{frequency} > 0.01$) in this population using version 0.1.16, VCFtools ([@c16]), and identified overlaps with differentially methylated CpGs using BEDTools ([@c48]).

Replication studies were conducted for differentially methylated CpG sites and DMRs identified in MACHS, using $\text{CD}4^{+}$ DNA methylation data from two different study populations. The first study, WakeMed Smoking Epigenetics Study (SMKE), profiled DNA methylation using the Illumina Infinium MethylationEPIC array in cord blood $\text{CD}4^{+}$ cells isolated with $\text{CD}4^{+}$ Dynabeads (Invitrogen) from a group of 30 newborns ($n = 14$ exposed vs. $n = 16$ unexposed to sustained maternal tobacco smoke), who were recruited from the WakeMed hospital in Raleigh, North Carolina. The second study, Epigenetic Biomarkers of Tobacco Smoke Exposure, profiled DNA methylation in adult $\text{CD}4^{+}$ cells from a subset of smokers and nonsmokers using three different methods: *a*) Illumina's EPIC array ($n = 9$ smokers; $n = 11$ nonsmokers), *b*) Illumina's HumanMethylation450K ($n = 59$ smokers; $n = 72$ nonsmokers) array, and *c*) reduced representation bisulfite sequencing (RRBS) ($n = 9$ smoking; $n = 10$ nonsmoking women). These participants were recruited at the National Institute of Environmental Health Sciences (NIEHS) Clinical Research Unit (CRU) ([@c56]). Methods for replication analyses and participant demographics for the replication studies are described in more detail in Supplemental Materials (see "Replication Look-Up Analyses" and Tables S1--S4).

Look-up analyses were conducted for DMRs identified in a previous study of maternal tobacco smoke exposure during pregnancy, which profiled DNA methylation in whole cord blood samples using WGBS ([@c4]). Additionally, look-up analyses were conducted *a*) for 25 of the 26 CpGs that were identified as differentially methylated ($p_{\text{Bonferroni}} < 0.05$) by sustained maternal tobacco smoke exposure during pregnancy in whole cord blood in an Infinium 450K array study ([@c35]), many of which have been widely replicated, that were also represented in the MACHS WGBS dataset; and *b*) for 3,258 CpGs on the 450K array that were identified as differentially methylated ($p_{\text{FDR}} < 0.05$) in relation to both sustained and any maternal smoking in meta-analyses conducted by the Pregnancy and Childhood Epigenetics (PACE) consortium ([@c34]), which were also represented in the MACHS WGBS dataset.

Results {#s3}
=======

Characteristics of Study Participants {#s3.1}
-------------------------------------

Characteristics of the subset of MACHS participants with WGBS data are shown separately by exposure group and are compared with the entire MACHS study population in [Table 1](#t1){ref-type="table"}. For the subset of participants with WGBS data, the $\text{mean} \pm \text{standard}\,\text{deviation}\,\left( \text{SD} \right)$ maternal age at pregnancy was $26 \pm 7\; y$, and the $\text{mean} \pm \text{SD}$ maternal prepregnancy BMI was $29.2 \pm 5.6$. There were more male (65%) compared with female (45%) newborns in the current study, and the $\text{mean} \pm \text{SD}$ gestational age was $38 \pm 2\;{wk}$, with 20% of babies born preterm. Sixty-five percent of mothers included in the study reported that they worked during pregnancy. Measured covariates were similar between exposure groups ([Table 1](#t1){ref-type="table"}). The subset of participants with WGBS data were generally similar to the overall MACHS cohort, although $\sim 6\%$ of MACHS participants reported having diabetes prior to pregnancy, compared with 0% in the WGBS subset, which was by design ([Table 1](#t1){ref-type="table"}). There were also fewer male babies and fewer mothers who reported working during pregnancy in the overall MACHS cohort ([Table 1](#t1){ref-type="table"}).

Differentially Methylated CpG Sites and Regions {#s3.2}
-----------------------------------------------

We identified 10,381 CpG sites that were differentially methylated in cord blood between newborns with and without exposure to maternal smoking *in utero* ($p_{\text{FDR}} < 0.05$) (Excel Table S1). None of the sites were statistically significant after applying a more conservative Bonferroni correction (number of $\text{tests} = 26,674,173$; $\text{Bonferroni}\,\text{threshold} = 1.9 \times 10^{- 9}$; smallest $p = 5.7 \times 10^{- 8}$). There was evidence of some genomic inflation ($\lambda = 1.25$). Of the 10,381 differentially methylated CpGs identified, 169 (1.6%) overlapped an SNP identified as common (minor allele frequency $> 0.01$) in the 1000 Genomes MXL population (Excel Table S1). In our visual inspection of a subset of highly significant CpGs with moderate percentage methylation differences (10--11%), we did identify some outliers (Figure S1).

From the 10,381 differentially methylated CpGs, MethPipe identified 1,533 DMRs by merging neighboring CpGs that had a $p_{\text{FDR}} < 0.05$. Of these DMRs, 557 contained a minimum of three CpG sites with both a raw and FDR-adjusted $p < 0.05$ and were therefore retained for downstream analyses (Excel Table S2). Of these 557 DMRs, 249 DMRs were hypomethylated and 308 were hypermethylated in tobacco smoke exposed, compared with unexposed, newborns. The 10,381 differentially methylated CpGs and 557 DMRs are shown by chromosome in Figure S2. The median absolute methylation difference for the 557 DMRs was 12%, and the largest absolute methylation difference was 40% (Figure S3). These DMRs spanned from 8 to 568 base pairs, with a median length of 149 base pairs (Figure S2). Although the majority of DMRs contained fewer than 10 CpGs with both a raw $p\text{-value} < 0.05$ and $p_{\text{FDR}} < 0.05$, one DMR, located in the promoter of pseudogene *HSPA7*, contained as many as 31. These 31 CpGs comprise a subset of 57 CpGs that were found to be differentially methylated ($p_{\text{FDR}} < 0.05$) in the promoter region of *HSPA7* in individual CpG analyses. These 57 CpGs represent more than half of the 106 CpGs located in the *HSPA7* promoter that were represented in the MACHS dataset; all but one of these 57 CpGs was hypomethylated in the maternal tobacco smoke exposed, compared with unexposed, group. The 20 DMRs with the largest methylation differences are listed with their nearest genes in [Table 2](#t2){ref-type="table"}. The majority of these DMRs were hypermethylated and located within intergenic regions.

###### 

The twenty DMRs with the largest methylation differences.

Table 2 has 7 columns, namely, DMR position, percentage methylation difference, number of CpGs, genomic location, nearest gene(s), distance from gene (base pairs), and mean coverage per CpG in the DMR.

  Position                     Percent methylation difference   No. of CpGs[*a*](#TF9){ref-type="table-fn"}   Genomic location   Nearest gene(s)                 Distance from gene (base pairs)   Mean coverage per CpG in DMR
  ---------------------------- -------------------------------- --------------------------------------------- ------------------ ------------------------------- --------------------------------- ------------------------------
  Hypermethylated                                                                                                                                                                                  
   Chr10:46775380-46775612     39.7                             7                                             Intergenic         *GLUD1P7*                       7,033                             0.7
   Chr17:7114926-7114953       39.2                             3                                             Intron             *DLG4*                          0                                 1.7
   Chr2:144749232-144749290    36.6                             5                                             Intron             *GTDC1*                         0                                 0.8
   Chr7:38308302-38308354      35.3                             3                                             3'End              *TRGC2, TCRGC2, TARP, Z22690*   0, 0, 0, 0                        4.0
   Chr8:38533279-38533327      34.8                             3                                             Intergenic         *TACC1*                         52,376                            5.8
   Chr5:26725725-26725747      33.3                             3                                             Intergenic         *CDH9*                          154,961                           0.7
   Chr21:39004308-39004421     31.9                             3                                             Intron             *KCNJ6*                         0                                 4.9
   Chr22:21663324-21663499     31.4                             8                                             Intergenic         *POM121L8P*                     11,308                            1.1
   Chr15:25200647-25200780     31.3                             4                                             Promoter           *SNRPN, SNURF*                  0                                 1.4
   Chr12:58229294-58229355     30.8                             3                                             Intron             *CTDSP2*                        0                                 7.6
   Chr10:123100131-123100324   30.5                             5                                             Intergenic         *FGFR2*                         137519                            7.4
   Chr16:57343206-57343353     29.9                             6                                             Intergenic         *TRNA_Leu*                      8,731                             3.1
   Chr17:27359874-27360049     29.0                             4                                             Intergenic         *PIPOX*                         9,868                             5.0
   Chr4:1607004-1607368        28.6                             8                                             Intergenic         *AX748388*                      29,037                            3.2
  Hypomethylated                                                                                                                                                                                   
   Chr6:171026627-171026778    $- 39.8$                         9                                             Intergenic         *BC036251*                      20,591                            1.4
   Chr5:564378-564471          $- 38.5$                         5                                             Intergenic         *MIR4456*                       28,380                            0.8
   Chr1:18343023-18343127      $- 34.4$                         3                                             Intergenic         *IGSF21*                        91,112                            8.9
   Chr4:3295539-3295663        $- 30.5$                         3                                             Intron             *RGS12*                         0                                 4.9
   Chr9:36154747-36154804      $- 29.6$                         3                                             Intron             *GLIPR2*                        0                                 7.6
   Chr5:177209275-177209375    $- 29.4$                         4                                             Promoter           *FAM153A*                       0                                 3.6

Note: Chr, chromosome; DMR, differentially methylated region.

^*a*^Number of CpGs in the DMR of interest with a raw and false discovery rate-adjusted $p\text{-value} < 0.05$.

Genomic Context of Differentially Methylated Regions and Enrichment in Key Regulatory Regions {#s3.3}
---------------------------------------------------------------------------------------------

Compared with a random sample of similar-sized regions in the genome, DMRs were enriched at promoter, exon, and 3' end regions ([Table 3](#t3){ref-type="table"}). In contrast, there were significantly fewer DMRs within intergenic regions than would be expected by chance ([Table 3](#t3){ref-type="table"}). Results were similar when DMRs were evaluated separately by those that were hyper- vs. hypomethylated in the tobacco smoke exposed, compared with the unexposed, group, and median (range) percentage methylation differences were generally similar across genomic regions (Figure S4).

###### 

Enrichment of DMRs within regions of interest.

Table 3 lists values for the number of observed versus expected DMRs within regions of interest, as well as the enrichment p-value, for the following categories: promoters, exons, introns, 3 prime end, intergenic, all enhancers, T cell enhancers, CD4+ DNase sensitive regions (ENCODE), and CD4+ CTCF binding sites.

                                                                Observed   Expected   Enrichment *p*-Value[*a*](#TF11){ref-type="table-fn"}
  ------------------------------------------------------------- ---------- ---------- -------------------------------------------------------
  Promoters                                                     52         15         $3.4 \times 10^{- 14}$
  Exons                                                         33         14         $8.0 \times 10^{- 6}$
  Introns                                                       237        229        0.49
  3' End                                                        26         14         $4.1 \times 10^{- 3}$
  Intergenic                                                    209        285        $1.3 \times 10^{- 10}$
  All enhancers                                                 11         3          $4.8 \times 10^{- 4}$
  T-cell enhancers                                              2          1          0.11
  $\text{CD}4^{+}$ DNase-sensitive regions (ENCODE)             35         5          $< 2.2 \times 10^{- 16}$
  $\text{CD}4^{+}$ transcription factor binding sites (ReMap)   34         6          $1.8 \times 10^{- 17}$
  $\text{CD}4^{+}$ CTCF binding sites                           11         2          $3.2 \times 10^{- 5}$

Note: Five hundred fifty-seven DMRs were identified in cord blood $\text{CD}4^{+}$ cells from newborns exposed, compared with newborns unexposed, to maternal tobacco smoke. These 557 DMRs were identified from a total of 10,381 differentially methylated CpGs using the MethPipe pipeline. Differentially methylated CpGs were identified using beta-binomial regression models, which were adjusted for baby's sex and maternal working status during pregnancy. DMR, differentially methylated region; ENCODE, Encyclopedia of DNA Elements.

^*a*^*p*-Value from Fisher's exact test.

DMRs were also significantly enriched within FANTOM5 enhancers, $\text{CD}4^{+}$ DNase-sensitive regions, and at $\text{CD}4^{+}$ transcription factor binding sites, including CTCF binding sites ([Table 3](#t3){ref-type="table"}). Results were similar when DMRs were evaluated separately by those that were hypermethylated vs. hypomethylated in the exposed, compared with the unexposed, group (Table S5). Of the 557 DMRs identified, 11 overlapped active enhancer regions, two of which are active in T cells. Predicted targets of these enhancer regions and descriptive information for overlapping DMRs are shown in Table S6. The two DMRs overlapping T-cell enhancers were hypomethylated among the exposed, compared with unexposed, newborns. One DMR (chr8:141,108,929-141,109,987) had a methylation difference of $- 11.7\%$. The predicted target of this enhancer was the promoter region of *KCNK9* ($r = 0.73$) ([@c3]; [@c62]), which is imprinted in the brain ([@c63]). This same DMR also overlapped a $\text{CD}4^{+}$ DNAse-sensitive region (chr8:141,109,195-141,109,405) and CTCF binding region (chr8:141,109,278-141,109,552). The second DMR (chr21:44,104,688-44,105,340) had a methylation difference of $- 15.0\%$. The enhancer overlapping this DMR had two predicted targets: the promoter region of *NDUFV3* ($r = 0.92$), which codes for a mitochondrial enzyme, and also *ABCG1* ($r = 0.66$) ([@c3]; [@c62]), which plays an important role in cellular lipid homeostasis ([@c60]). None of the DMRs overlapped ubiquitous enhancers.

Gene Set Enrichment Analyses {#s3.4}
----------------------------

A total of 564 genes were annotated to the 557 DMRs (Excel Table S2). Of these genes, 385 directly overlapped a DMR (Excel Table S2). These genes were not significantly enriched in any PANTHER pathways or significantly associated with any GO biological processes after adjusting for multiple testing.

Predicted Targets of Differentially Methylated MicroRNA Genes {#s3.5}
-------------------------------------------------------------

Of the 385 genes directly overlapping DMRs, four coded for miRNAs (*miR-29b-2*, *miR4750*, *miR1914*, and *miR646HG*). There were 1,065 predicted target genes identified for these miRNAs (Excel Table S3); these genes were associated with 15 GO biological process terms, which remained statistically significant after adjusting for multiple testing (Excel Table S4). Seven of these GO terms were related to the regulation of transcription or gene expression.

Replication Studies {#s3.6}
-------------------

Because we were unable to identify other WGBS studies of tobacco smoke exposure in $\text{CD}4^{+}$ cells, we sought to replicate our results in populations with array-based DNA methylation measures for $\text{CD}4^{+}$ cells. However, $< 5\%$ (485/10,381) of the differentially methylated CpGs identified in MACHS are covered on the Infinium EPIC array, and $< 4\%$ (399/10,381) are covered on the Infinium 450K array. Results for the 485 differentially methylated CpGs identified in MACHS ($p_{\text{FDR}} < 0.05$), which are represented on the EPIC array, are shown for the WakeMed SMKE ($n = 14$ newborns exposed to sustained maternal smoking during pregnancy; $n = 16$ unexposed) and NIEHS CRU replication study ($n = 9$ smoking; $n = 11$ nonsmoking adults) in Excel Table S5. The 399 differentially methylated CpGs identified in MACHS, which are represented on the 450K array, are also shown in this table for the NIEHS CRU replication study ($n = 59$ smoking; $n = 72$ nonsmoking adults). Although only 60 of the 485 CpGs examined had a raw $p < 0.05$ in the WakeMed SMKE study, this was a larger number than would be expected by chance ($p_{\text{Kolmogorov}\text{-}\text{Smirnov}} = 5.3 \times 10^{- 6}$). Of these 60 CpGs, 33 were differentially methylated in the same direction in both SMKE and MACHS ([Table 4](#t4){ref-type="table"}). Distributions of methylation levels within each of the 33 CpGs that replicated are shown for both MACHS and SMKE in Figure S5. The replication rate for CpGs with a mean coverage $\geq 10 \times$ (8.1%) did not differ (*p*-value from Fisher's exact $\text{test} = 0.73$) from the replication rate for CpGs with a mean coverage $< 10 \times$ (6.7%). One of the CpGs that replicated (located in the promoter of *SLC7A8*; $\text{mean}\,\text{coverage} = 8.9 \times$) was found to be hypomethylated in the tobacco smoke exposed, compared with unexposed, group in both MACHS and the SMKE study, and was also hypomethylated in smokers compared with nonsmokers in both the EPIC and 450K NIEHS CRU studies of adult $\text{CD}4^{+}$ cells (Excel Table S5). Given the reproducibility of this result, we evaluated whether any other CpGs within *SLC7A8* that were identified as differentially methylated in MACHS replicated; of the 14 CpGs that could be queried, five were differentially methylated (raw $p < 0.05$) in the same direction in at least one of the replication studies (Excel Table S5). We also evaluated whether any of the CpGs contained within the 20 DMRs with the largest percentage methylation differences ([Table 2](#t2){ref-type="table"}) replicated in the WakeMed SMKE study. However, none of the six CpGs that could be queried replicated (Table S7).

###### 

Differentially methylated CpGs identified in MACHS that were replicated in the SMKE cord blood $\text{CD}4^{+}$ study ($n = 14$ exposed; $n = 16$ unexposed).

Table 4 has 8 columns, namely, MACHS WGBS CpG, MACHS percentage methylation difference, mean coverage, WakeMed EPIC CpG, percentage methylation difference, raw p-value, nearest gene, and distance (basepairs).

  MACHS WGBS CpG    Percent methylation difference   Mean coverage   WakeMed EPIC CpG                                Percent methylation difference   Raw *p*-value           Nearest gene     Distance (base pair)
  ----------------- -------------------------------- --------------- ----------------------------------------------- -------------------------------- ----------------------- ---------------- ----------------------
  Chr1:2112005      10.8                             4.9             cg02066716                                      0.1                              0.05                    *PRKCZ*          0
  Chr1:108113976    5.0                              7.2             cg24950918                                      1.9                              0.02                    *VAV3*           0
  Chr1:172582730    5.5                              5.2             cg15874871                                      0.9                              0.04                    *SUCO*           $- 1,756$
  Chr3:194854341    8.9                              11.1            cg11796219                                      1.1                              $1.6 \times 10^{- 3}$   *XXYLT1*         0
  Chr5:8457720      $- 13.9$                         7.3             cg18371052                                      $- 6.0$                          $7.3 \times 10^{- 3}$   *LINC02226*      42
  Chr6:33255589     6.1                              6.5             cg00783244                                      0.7                              0.05                    *WDR46*          0
  Chr6:155475641    39.9                             9.5             cg05104189                                      0.4                              0.04                    *TIAM2*          0
  Chr7:637221       3.9                              5.1             cg14871771                                      1.9                              0.02                    *PRKAR1B*        0
  Chr7:70258725     9.1                              7.0             cg02327773[^*a*^](#TF13){ref-type="table-fn"}   0.5                              $1.7 \times 10^{- 3}$   *AUTS2*          839
  Chr7:70258752     12.8                             8.1             cg18542967                                      0.5                              0.03                    *AUTS2*          866
  Chr8:2586007      $- 18.7$                         9.6             cg02210441                                      $- 8.1$                          $5.3 \times 10^{- 3}$   *LOC101927815*   49
  Chr8:23179282     $- 17.4$                         8.5             cg12060669                                      $- 8.5$                          0.04                    *LOXL2*          0
  Chr8:74282930     24.8                             9.8             cg20982046                                      2.5                              $7.0 \times 10^{- 3}$   *RDH10-AS1*      14,233
  Chr9:18493887     7.1                              8.7             cg13552832                                      0.7                              0.03                    *ADAMTSL1*       0
  Chr10:82296190    $- 8.6$                          5.7             cg09623377                                      $- 3.9$                          0.02                    *SH2D4B*         1,467
  Chr10:105420500   $- 20.1$                         11.3            cg19007269                                      $- 6.8$                          $3.3 \times 10^{- 3}$   *SH3PXD2A*       0
  Chr11:73625665    8.3                              5.5             cg08665076                                      1.6                              0.02                    *PAAF1*          0
  Chr12:313103      $- 14.3$                         3.3             cg20188212                                      $- 0.3$                          0.05                    *SLC6A12*        0
  Chr12:133343427   7.7                              9.9             cg25939853                                      4.3                              $3.2 \times 10^{- 3}$   *GOLGA*          2,067
  Chr14:23623727    $- 9.4$                          8.9             cg08104568                                      $- 2.4$                          0.03                    *SLC7A8*         0
  Chr16:88689493    19.6                             4.9             cg01018360                                      0.5                              0.04                    *ZC3H18*         0
  Chr17:8867337     11.5                             10.7            cg25342409                                      5.2                              0.02                    *PIK3R5*         0
  Chr17:76037363    $- 16.3$                         7.7             cg07787614                                      $- 7.6$                          0.04                    *TNRC6C*         0
  Chr18:77487393    0.6                              5.0             cg13817822                                      3.4                              0.03                    *CTDP1*          0
  Chr18:3412781     5.6                              8.1             cg04431731                                      0.4                              0.04                    *TGIF1*          0
  Chr19:613432      $- 12.8$                         3.9             cg00587228[^*a*^](#TF13){ref-type="table-fn"}   $- 6.2$                          0.01                    *HCN2*           0
  Chr19:46915775    $- 16.9$                         4.6             cg17375267                                      $- 3.9$                          0.04                    *CCDC8*          0
  Chr21:44105264    $- 19.9$                         4.7             cg23590273                                      $- 6.3$                          0.02                    *PDE9A*          0
  Chr21:44105473    $- 23.2$                         4.9             cg16784985                                      $- 8.5$                          $7.4 \times 10^{- 3}$   *PDE9A*          0
  Chr22:42548355    $- 4.3$                          4.4             cg17050807                                      $- 2.2$                          0.02                    *TCF20*          7,663
  ChrX:48685181     $- 17.1$                         3.4             cg09513996                                      $- 13.2$                         $4.6 \times 10^{- 3}$   *ERAS*           0
  ChrX:48685302     $- 12.0$                         5.1             cg22656275                                      $- 7.6$                          0.02                    *ERAS*           0
  ChrX:134048711    $- 6.2$                          3.5             cg24138084                                      $- 3.4$                          0.01                    *MOSPD1*         0

Note: CpGs were considered replicated if the raw *p*-value in the SMKE study was $< 0.05$ and the percent methylation difference was in the same direction as that observed in MACHS. The exposed group consisted of 14 newborns whose mothers smoked during pregnancy in SMKE. The unexposed group consisted of 16 newborns whose mothers were lifetime nonsmokers. DNA methylation was measured in cord blood $\text{CD}4^{+}$ cells by the Infinium EPIC array for the SMKE study. Chr, chromosome; MACHS, Maternal and Child Health Study; WGBS, whole-genome bisulfite sequencing.

These CpGs have previously been found to be polymorphic or to be targeted by a probe with a single-nucleotide polymorphism in the single base pair extension ([@c11]).

Results for the nine DMRs that were identified in MACHS that could be queried in the NIEHS CRU RRBS study of adult $\text{CD}4^{+}$ cells ($n = 9$ smoking; $n = 10$ nonsmoking women) are shown in [Table 5](#t5){ref-type="table"}. Four of these DMRs (shown in [Figure 1](#f1){ref-type="fig"}) were significantly differentially methylated ($p < 0.05$) in the same direction in both studies ([Table 5](#t5){ref-type="table"}).

###### 

DMR replication results.

Table 5 has 7 columns, namely, M A C H S W G B S CpG, M A C H S percentage Methylation difference, NIEHS C R U RRBS DMR, NIEHS C R U percentage methylation difference, Raw p value, Nearest gene, and distance.

  MACHS WGBS DMR             MACHS percent methylation difference   NIEHS CRU RRBS DMR         NIEHS CRU percent methylation difference   Raw *p*-Value   Nearest gene   Distance (base pair)
  -------------------------- -------------------------------------- -------------------------- ------------------------------------------ --------------- -------------- ----------------------
  Chr1:6852075-6852260       $- 14.4$                               Chr1:6852171-6852205       1.8                                        0.03            *CAMTA1*       0
  Chr1:54701016-54701221     $- 13.3$                               Chr1:54701218-54701382     2.9                                        0.01            *SSBP3*        0
  Chr2:237476491-237476692   $- 19.1$                               Chr2:237476624-23747642    15.6                                       0.01            *CXCR7*        0
  Chr6:2764191-2764384       11.1                                   Chr6:2764287-2764557       4.1                                        0.02            *WRNIP1*       1,281
  Chr7:150498649-150498694   $- 13.9$                               Chr7:150498243-150498694   6.7                                        0.01            *TMEM176A*     0
  Chr9:72027018-72027281     17.8                                   Chr9:72026918-72027130     10.7                                       0.04            *APBA1*        15,167
  Chr11:47952753-47952964    $- 7.8$                                Chr11:47952767-47952802    $- 2.6$                                    0.01            *PTPRJ*        49,145
  Chr12:7781003-7781099      17.1                                   Chr12:7780979-7781052      $- 19.7$                                   0.02            *APOBEC1*      20,896
  Chr19:47273681-4727802     6.7                                    Chr19:47273536-47273793    3.6                                        0.02            *SLC1A5*       4,337

Note: Chr, chromosome; DMR, differentially methylated region; MACHS, Maternal and Child Health Study; NIEHS CRU, National Institute of Environmental Health Sciences Clinical Research Unit; RRBS, reduced representation bisulfite sequencing; WGBS, whole-genome bisulfite sequencing.

Nine DMRs identified in MACHS could be queried in a reduced representation bisulfite sequencing study conducted in $\text{CD}4^{+}$ cells from a subset of women from the NIEHS CRU study. DMRs identified in MACHS were considered replicated if *a*) they overlapped a DMR identified in the NIEHS CRU study; *b*) the overlapping DMR had a $p < 0.05$; and *c*) the percent methylation difference for the overlapping DMR was in the same direction as the DMR identified in MACHS.

![The four differentially methylated regions (DMRs) identified in the Maternal and Child Health Study (MACHS), which replicated in the National Institute of Environmental Health Sciences Clinical Research Unit (NIEHS CRU) reduced representation bisulfite sequencing study of adult $\text{CD}4^{+}$ cells, are depicted in (A--D). DMRs were considered replicated if *a*) the chromosome coordinates overlapped between the two studies; *b*) the *p*-value for the NIEHS CRU study DMR was $< 0.05$; and *c*) the percent methylation difference was in the same direction. Coordinates for each DMR and the percent methylation difference (comparing maternal tobacco smoke exposed with unexposed newborns) are indicated at the top of each panel. The location of each DMR is indicated by a vertical red line in the ideogram of its respective chromosome. Plots show the percent methylation levels (*y*-axis) for each MACHS participant at each CpG contained in the DMR. Chromosome positions for CpGs are indicated in gray (*x*-axis) above the plot. Percent methylation levels for participants in the exposed group are shown as light blue dots, and mean percent methylation levels for each CpG are connected by light blue lines. Percent methylation levels for participants in the unexposed group are shown as dark blue dots, and mean percent methylation levels for each CpG are connected by dark blue lines. Vertical gray bars highlight CpGs that were identified as differentially methylated with both a raw $p < 0.05$ and a $p < 0.05$ after accounting for correlations with neighboring CpGs and multiple testing, using the Benjamini-Hochberg method to control the false discovery rate.](ehp3398_f1){#f1}

Comparisons with Previous Studies of Maternal Tobacco Smoke Exposure and DNA Methylation {#s3.7}
----------------------------------------------------------------------------------------

A previous study by Bauer et al. examined associations between maternal smoking during pregnancy and whole cord blood DNA methylation, using WGBS ([@c4]). Using a smoothing method, they identified 8,409 DMRs, with an FDR of 12.4%. Only six of the 557 DMRs ($p_{\text{FDR}} < 0.05$) identified in MACHS overlapped those identified by Bauer et al. (Table S8). The nearest genes to these six DMRs included *TRNA_VAL*, *RIN3*, *MIR646HG*, *ZNF890P*, *APBA1*, *ANK1*, and *NKX6-3* (the latter two genes were associated with one DMR, located on chromosome 8). Two of these DMRs (one near *TRNA_VAL* and one near *APBA1*) were differentially methylated in the same direction (both were hypermethylated in the exposed, compared with unexposed, group), and one of these DMRs (chr9:72,027,018-72,027,281) was also identified in the NIEHS CRU RRBS replication study of $\text{CD}4^{+}$ cells from smoking and nonsmoking women. Across all three studies, this DMR was found to be hypermethylated in the tobacco smoke exposed, compared with unexposed, group (percent methylation differences: 17.8% in MACHS, 10.8% in the WGBS whole cord blood study by Bauer et al., and 10.7% in the NIEHS CRU RRBS study of adult $\text{CD}4^{+}$ cells).

We also conducted a look-up analysis for 26 CpGs identified as differentially methylated ($p_{\text{Bonferroni}} < 0.05$) in cord blood by sustained maternal tobacco smoke exposure in a previous 450K array study, as many of these results have been widely replicated ([@c35]). Twenty-five of the 26 CpGs were represented in the MACHS WGBS results and could therefore be queried. Sequencing coverage at these CpGs ranged from $1.9–10.6 \times$. None of the 25 CpGs were found to be differentially methylated in MACHS (raw *p*-value and $p_{\text{FDR}} > 0.05$), although the directions of associations were similar for several sites ([Table 6](#t6){ref-type="table"}). For example, all four of the CpGs that have previously been identified as differentially methylated in *AHRR* were differentially methylated in the same direction in MACHS. To determine whether the inconsistencies between the Joubert et al. study and MACHS were due to the differences in the cell types examined, we conducted a look-up analysis for the same CpGs in the WakeMed SMKE EPIC array study of cord blood $\text{CD}4^{+}$ cells. Of the 26 differentially methylated CpGs identified by Joubert et al., 23 are represented on the EPIC array; of these, 11 (47.8%) were significantly ($p < 0.05$) differentially methylated in the same direction in the SMKE study. This included one CpG that could not be examined in MACHS. For the 10 CpGs that were differentially methylated in SMKE but not MACHS, the median coverage was $4.7 \times$. This did not differ ($p_{\text{Wilcoxon}} = 0.31$) from the median coverage ($7.8 \times$) of the 12 CpGs that were not differentially methylated in either SMKE or MACHS.

###### 

Look-up results for 26 CpGs identified as differentially methylated by maternal tobacco smoke exposure by Joubert et al. ([@c35]) in MACHS and the SMKE study.

Table 6 has 8 columns, namely, CpG, position, gene, MoBa 450K, which is segregated into percentage methylation difference and p-value, NEST 450k, which is segregated into percentage methylation difference and p-value, and MACHS (WGBS), which is segregated into percentage methylation difference, p-value, and PFDR, and average coverage, and WakeMed SMKE (EPIC), which is segregated into percentage methylation difference and p-value \[Table 6 lists CpGs, their positions, and corresponding genes in the first, second, and third columns, respectively. The corresponding percentage of methylation difference and p-value for MoBa and NEST in Joubert et al. 2012, and for percentage of methylation difference, p-value, and average coverage values for WGBS in MACHS, and for percentage of methylation difference and p-value for EPIC in WakeMed SMKE are listed in the adjacent columns.

  CpG                                             Position         Gene                [@c35]     MACHS                    WakeMed SMKE                                                                              
  ----------------------------------------------- ---------------- ------------------- ---------- ------------------------ -------------- ----------------------- ---------- ---------- ---------- ------ ---------- -----------------------
  cg10399789                                      Chr1:92945668    *GFI1*              $- 3.7$    $1.1 \times 10^{- 10}$   $- 3.4$        0.02                    $- 2.6$    0.44       0.44       5.9    $- 0.5$    0.44
  cg09662411                                      Chr1:92946132    *GFI1*              $- 6.6$    $3.0 \times 10^{- 17}$   $- 6.8$        $2.3 \times 10^{- 3}$   6.8        0.26       0.78       3.3    $- 1.6$    0.61
  cg06338710                                      Chr1:92946187    *GFI1*              $- 5.8$    $5.0 \times 10^{- 14}$   $- 5.2$        $2.6 \times 10^{- 3}$   $- 4.3$    0.57       0.66       4.0    $- 0.7$    0.39
  cg18146737                                      Chr1:92946700    *GFI1*              $- 12.3$   $3.3 \times 10^{- 25}$   $- 15.1$       $3.7 \times 10^{- 3}$   0.8        0.66       0.64       4.3    $- 1.5$    0.03
  cg12876356                                      Chr1:92946825    *GFI1*              $- 11.9$   $1.7 \times 10^{- 25}$   $- 10.5$       $1.5 \times 10^{- 3}$   $- 0.02$   0.15       0.43       5.1    $- 2.1$    0.01
  cg18316974                                      Chr1:92947035    *GFI1*              $- 7.1$    $3.2 \times 10^{- 20}$   $- 9.0$        $2.3 \times 10^{- 3}$   $- 4.3$    0.50       0.54       3.9    $- 0.6$    0.12
  cg09935388[^*b*^](#TF18){ref-type="table-fn"}   Chr1:92947588    *GFI1*              $- 13.7$   $2.7 \times 10^{- 31}$   $- 7.5$        $1.2 \times 10^{- 3}$   NA         NA         NA         NA     $- 5.9$    $5.0 \times 10^{- 4}$
  cg14179389                                      Chr1:92947961    *GFI1*              $- 8.6$    $2.6 \times 10^{- 25}$   $- 8.2$        $4.3 \times 10^{- 3}$   $- 3.4$    0.43       0.74       4.1    $- 10.7$   $1.9 \times 10^{- 3}$
  cg23067299[^*c*^](#TF19){ref-type="table-fn"}   Chr5:323907      *AHRR*              3.2        $4.12 \times 10^{- 9}$   3.7            $3.6 \times 10^{- 3}$   10.3       0.07       0.63       8.1    NA         NA
  cg03991871[^*c*^](#TF19){ref-type="table-fn"}   Chr5:368447      *AHRR*              $- 2.2$    $2.0 \times 10^{- 10}$   $- 2.3$        0.07                    $- 6.9$    0.52       0.86       8.2    NA         NA
  cg05575921                                      Chr5:373378      *AHRR*              $- 7.5$    $8.0 \times 10^{- 33}$   $- 7.7$        $3.0 \times 10^{- 4}$   $- 1.4$    0.79       $> 0.99$   7.3    $- 4.3$    $2.1 \times 10^{- 8}$
  cg21161138                                      Chr5:399360      *AHRR*              $- 2.3$    $8.9 \times 10^{- 10}$   $- 1.7$        $3.6 \times 10^{- 3}$   $- 0.05$   0.99       $> 0.99$   9.3    $- 3.2$    0.01
  cg11715943                                      Chr6:33091841    *HLA-DPB2*          $- 1.8$    $3.6 \times 10^{- 8}$    $- 0.3$        0.80                    1.7        0.69       0.96       7.8    1.2        0.11
  cg19089201                                      Chr7:45002287    *MYO1G*             1.4        $9.1 \times 10^{- 11}$   2.2            $9.2 \times 10^{- 3}$   0.6        0.71       0.43       3.5    0.4        0.05
  cg22132788[^*c*^](#TF19){ref-type="table-fn"}   Chr7:45002486    *MYO1G*             2.8        $4.8 \times 10^{- 18}$   2.1            $9.6 \times 10^{- 3}$   4.3        0.81       0.42       2.6    NA         NA
  cg04180046                                      Chr7:45002736    *MYO1G*             5.3        $2.9 \times 10^{- 19}$   4.9            $2.7 \times 10^{- 3}$   $- 5.1$    0.80       0.69       1.9    2.7        0.01
  cg12803068                                      Chr7:45002919    *MYO1G*             8.3        $1.3 \times 10^{- 19}$   3.8            $4.1 \times 10^{- 3}$   0.0        0.97       0.92       3.5    0.7        0.03
  cg04598670                                      Chr7:68697651    *ENSG00000225718*   $- 3.0$    $1.3 \times 10^{- 9}$    $- 5.3$        $3.6 \times 10^{- 3}$   $- 0.3$    0.96       $> 0.99$   10.3   $- 0.5$    0.89
  cg25949550                                      Chr7:145814306   *CNTNAP2*           $- 1.8$    $1.0 \times 10^{- 26}$   $- 2.5$        $2.5 \times 10^{- 3}$   1.1        0.73       0.61       10.6   $- 1.5$    $6.7 \times 10^{- 3}$
  cg03346806                                      Chr8:119157879   *EXT1*              $- 1.5$    $9.3 \times 10^{- 8}$    $- 0.1$        0.12                    5.8        0.21       0.81       6.9    0.6        0.17
  cg18655025                                      Chr14:91008005   *TTC7B*             $- 1.2$    $6.8 \times 10^{- 8}$    $- 1.1$        0.27                    6.0        0.21       0.82       9.0    $- 0.1$    0.24
  cg05549655                                      Chr15:75019143   *CYP1A1*            3.5        $2.4 \times 10^{- 10}$   3.8            $6.0 \times 10^{- 4}$   1.9        $> 0.99$   0.90       7.6    3.9        $6.9 \times 10^{- 3}$
  cg22549041                                      Chr15:75019251   *CYP1A1*            7.2        $8.9 \times 10^{- 9}$    8.9            $4.4 \times 10^{- 3}$   $- 8.7$    0.07       0.98       7.8    4.9        0.41
  cg11924019                                      Chr15:75019283   *CYP1A1*            3.2        $4.8 \times 10^{- 8}$    5.3            $8.0 \times 10^{- 4}$   $- 2.0$    0.57       0.98       8.2    1.3        0.68
  cg18092474                                      Chr15:75019302   *CYP1A1*            5.9        $10.0 \times 10^{- 9}$   5.3            $4.4 \times 10^{- 3}$   $- 4.5$    0.37       0.99       7.9    5.1        0.22
  cg12477880                                      Chr21:36259241   *RUNX1*             4.6        $7.6 \times 10^{- 10}$   4.0            0.09                    3.2        0.21       0.98       8.1    1.6        0.21

Note: Twenty-six CpGs have previously been identified as differentially methylated (after adjusting for multiple testing using the Bonferroni correction) in whole cord blood by maternal tobacco smoke exposure in two study populations (MoBa and NEST), evaluated by [@c35], and have been widely replicated in subsequent studies. Look-up analyses were therefore conducted for these CpGs in both MACHS and the SMKE study. Percent methylation differences and raw *p*-values are presented for each CpG by study. False discovery rate-adjusted *p*-values are also presented for MACHS. Chr, chromosome; FDR, false discovery rate; MACHS, Maternal and Child Health Study; MoBa, Norwegian Mother and Child Cohort Study; NEST, Newborn Epigenetics Study; WGBS, whole-genome bisulfite sequencing.

Raw *p*-values from RADmeth beta-binomial regression models were adjusted for correlations with neighboring CpGs, as described previously ([@c19]), and were subsequently adjusted for multiple testing using the Benjamini-Hochberg method to control the false discovery rate.

Since all reads in the exposed and unexposed group were methylated in MACHS, RADMeth did not calculate a *p*-value for this CpG.

These CpGs are not represented on the Infinium EPIC array and therefore could not be examined in the SMKE study.

We also conducted a look-up analysis for CpGs that were identified as differentially methylated ($p_{\text{FDR}} < 0.05$) in whole cord blood in relation to both sustained and any maternal smoking during pregnancy in meta-analyses conducted by the PACE consortium ([@c34]). Of the 3,272 differentially methylated CpGs ($p_{\text{FDR}} < 0.05$) identified by PACE, 3,258 were represented in the MACHS WGBS dataset and could therefore be evaluated (Excel Table S6). Of these CpGs, 213 were differentially methylated in MACHS based on a raw $p < 0.05$, and 267 were differentially methylated after adjusting for correlations with proximal CpGs ($p_{\text{neighbor}} < 0.05$). These numbers are higher than would be expected by chance ($p_{\text{Kolmogorov}\text{-}\text{Smirnov}} = 3.9 \times 10^{- 4}$ and $3.2 \times 10^{- 11}$, respectively). Of the 213 CpGs with a raw $p < 0.05$, 123 were differentially methylated in the same direction in MACHS. Results did not differ for CpGs with an average coverage $\geq 10 \times$ vs. $< 10 \times$ ($p\text{-value}\,\text{from}\,\text{chi}\text{-square}\,\text{test} = 1$).

Discussion {#s4}
==========

Although earlier studies have evaluated the impact of maternal smoking during pregnancy on DNA methylation patterns, the majority used candidate gene approaches or methylation arrays, which cover a small fraction ($< 5\%$) of the $> 28\,\text{million}$ CpG sites in the human genome, and have traditionally focused on promoter regions. Using WGBS with $6.5 \times$ coverage as an alternative approach, we were able to interrogate $> 26\,\text{million}$ CpG sites, including those located distally from genes, and identified 557 regions that were differentially methylated by exposure to maternal smoking *in utero*. While we observed enrichment of DMRs within promoter regions, we also observed enrichment in enhancer regions, which have been largely uninvestigated, and in $\text{CD}4^{+}$ DNase-sensitive regions and transcription factor binding sites, including binding sites for CTCF, which are methylation sensitive and regulate gene expression via alterations to the three-dimensional structure of the genome ([@c58]).

To our knowledge, only one previous study, conducted by Bauer et al. ([@c4]), has utilized WGBS to investigate the effects of maternal tobacco smoke exposure during pregnancy on the newborn methylome. Similar to our findings, Bauer et al. observed significant enrichment of DMRs within enhancer regions. However, only six of the DMRs identified by Bauer et al. overlapped those identified by MACHS. Since the smoothing method used by Bauer et al. has been shown to yield similar results as the method used in the current study (MethPipe) ([@c19]), other study differences likely contributed to these discrepancies. Two potential explanations include the fact that Bauer et al. evaluated sustained maternal smoking during pregnancy and measured DNA methylation in whole blood, similar to most previous studies ([@c10]; [@c17]; [@c31]; [@c35]; [@c40]; [@c44]; [@c49]; [@c50]; [@c51]), whereas MACHS evaluated any maternal smoking during pregnancy and focused on $\text{CD}4^{+}$ cells. We also conducted a look-up analysis of 3,258 CpGs that were identified as differentially methylated in cord blood in relation to both any and sustained maternal smoking during pregnancy in meta-analyses conducted by the PACE consortium ([@c34]). While a larger number of these sites were differentially methylated in MACHS than would be expected by chance, only 123 (3.8%) were differentially methylated in the same direction with a raw $p < 0.05$.

To determine if the MACHS results were more reproducible in studies focusing on the same cell type, we conducted a series of replication analyses using data from studies that measured DNA methylation in $\text{CD}4^{+}$ cells from newborns or adults. We were able to query nine of the DMRs identified in MACHS in an RRBS study of $\text{CD}4^{+}$ cells from smoking and nonsmoking women (NIEHS CRU), four (44%) of which were significantly differentially methylated in the same direction. Of these four DMRs, one (chr9:72,027,018-72,027,281) was also identified in the whole cord blood WGBS study by Bauer et al. ([@c4]), which suggests that this region may be sensitive to tobacco smoke exposure in multiple blood cell types. In contrast with the DMR replication results, very few of the individual CpGs that were identified as differentially methylated in MACHS that could be queried were replicated. For example, of the 485 differentially methylated CpGs identified in MACHS that could be evaluated in an EPIC array study (SMKE) of cord blood $\text{CD}4^{+}$ cells, only 33 (6.8%) replicated. This suggests that a large fraction of the differentially methylated CpGs identified in MACHS that are represented on the EPIC array may be false positives, although it is possible that differences in participant characteristics, such as the different racial/ethnic compositions of the two study populations, and assay differences may also play a role. Although replication rates were low for the individual CpG results, one CpG (chr14:23,623,727) was identified as hypomethylated among maternal tobacco smoke exposed, compared with unexposed, newborns in both MACHS and the SMKE study, and was also found to be hypomethylated in smokers, compared with nonsmokers, in the NIEHS CRU study of adult $\text{CD}4^{+}$ cells, which was confirmed across two different platforms (i.e., the EPIC array and the 450K array). This result is therefore highly reproducible and suggests that this CpG, located in the promoter of amino acid transporter *SLC7A8* (Ren et al. 2017), may be sensitive to tobacco smoke exposure in $\text{CD}4^{+}$ cells, irrespective of life stage.

Since a subset of CpGs on the Infinium 450K array have been consistently identified as differentially methylated by sustained maternal smoking during pregnancy in whole cord blood ([@c35]), we were interested in evaluating whether these CpGs are also differentially methylated in $\text{CD}4^{+}$ cells. While some of these loci (e.g., all CpGs within *AHRR*) were differentially methylated in the same direction in MACHS, none were statistically significant. To determine if these discrepancies were driven by the different cell types examined, we conducted the same look-up analysis in the WakeMed SMKE EPIC array study of cord blood $\text{CD}4^{+}$ cells. Of the 23 CpGs that could be queried in SMKE, 11 (48%) were significantly differentially methylated in the same direction as that observed by Joubert et al., which suggests that about half of these CpGs are sensitive to tobacco smoke in $\text{CD}4^{+}$ cells, but the other half may not be. The latter result is not surprising, as there is evidence that exposure to maternal tobacco smoke *in utero* alters methylation patterns differently in certain leukocyte subpopulations ([@c4]; [@c55]). While it is currently unclear why the differentially methylated CpGs identified by Joubert et al. that replicated in SMKE were not also differentially methylated in MACHS, two possible explanations include the low coverage of the WGBS data, which may have reduced our statistical power, and the weaker exposure variable, as most of the MACHS mothers who smoked quit early in pregnancy.

Our study has some limitations that need to be considered. First, since MACHS participants were recruited at delivery, maternal samples were not collected during pregnancy, so exposure status could not be confirmed using maternal cotinine measures. However, women are more likely to underreport, rather than falsely report, that they smoked during pregnancy ([@c25]), and there is no reason to believe that this would occur differentially by newborn methylation status. Therefore, any potential exposure misclassification would have likely biased results toward the null. Another important consideration is that 40% of the women who reported smoking during pregnancy resided in a household with another smoker. However, previous studies have observed that the effects of maternal smoking on newborn DNA methylation are much stronger than those of other secondhand smoke exposures ([@c9]; [@c49]). An additional limitation is that there may have been some confounding by acculturation and/or ethnic substructure, as this information was not collected for MACHS participants, but both have been related to smoking behaviors ([@c18]; [@c37]). Importantly, a genomic inflation factor ($\lambda$) of 1.25 was observed for the current study, suggesting possible population stratification. We therefore cannot rule out the possibility that there may have been some genetic differences between groups, particularly given our small sample size. This is important as certain SNPs can destroy a CpG site and thus impact methylation at that locus. However, only a small fraction (1.6%) of the differentially methylated CpGs identified in MACHS overlapped common SNPs identified in a similar population (i.e., MXL of 1000 Genomes), so this likely had a minimal impact on our results. While we focused our study on sorted $\text{CD}4^{+}$ cells to minimize potential confounding by cell type heterogeneity, it is possible that maternal smoking during pregnancy may alter $\text{CD}4^{+}$ subpopulations, which could influence our results. Furthermore, we cannot necessarily generalize our findings to tissues other than $\text{CD}4^{+}$ cells. Another important limitation is that time from cord blood collection until sample processing varied between individuals. However, this did not differ by exposure status. While we observed significant enrichment of differentially methylated CpGs and DMRs within key regulatory elements, we did not measure gene expression and therefore cannot make definitive conclusions about the functional relevance of our findings. Follow-up studies will therefore be important to evaluate the impact of altered methylation levels at the sensitive regions identified in MACHS on related histone modifications and gene expression. Finally, it is possible that some of the observed associations between exposure to maternal smoking *in utero* and DNA methylation are driven by alterations in 5-hydroxymethycytosine and related modifications, as these marks are indistinguishable from 5-methylcytosine after bisulfite conversion ([@c30]).

For the current study, we used a method (RADMeth) that has been shown to perform well on very low--coverage WGBS data within a case--control context ([@c19]). Nevertheless, we cannot rule out the possibility that the low coverage of the MACHS WGBS data may have still contributed to some false positives, both for the individual CpG and DMR results, as RADmeth's performance on low-coverage data has not been evaluated in the context of environmental exposures, which have generally been associated with smaller methylation differences. However, while the replication rate for the individual CpG results was very low (6.8%), this did not differ by sequencing coverage, which suggests that other factors likely contributed to the poor replication rate. Since MethPipe does not systematically evaluate outliers, it is possible that outliers may have contributed to some false positives in our results. It is also possible that the modest coverage and the small sample size of the current study may have contributed to some false negatives. For example, none of the CpGs identified as differentially methylated by Joubert et al. ([@c35]) that have been widely replicated in studies of whole cord blood were significantly differentially methylated in MACHS. While some of these discrepancies may have been driven by differences in the cell types examined, a subset of these CpGs were found to be differentially methylated in the WakeMed study of cord blood $\text{CD}4^{+}$ cells, which suggests that other factors, such as the low coverage of our data or the weaker maternal smoking exposure in MACHS, may have contributed to the null results. Future WGBS studies with higher coverage, which focus on specific cell types, are greatly needed to address some of these limitations. In particular, down-sampling simulations using higher coverage datasets are needed to determine the average sequencing coverage and sample sizes required to minimize false positives and false negatives in studies investigating environmental impacts on the DNA methylome.

Despite these limitations, our study also had several unique strengths. By using WGBS, we were able to interrogate millions of CpG sites that have been understudied in relation to maternal tobacco smoke exposure, including CpGs within critical regulatory regions, such as enhancers, which tend to be underrepresented in methylation arrays. Since we looked at a much more homogenous cell population than has previously been investigated, our findings are also less subject to potential confounding by cell type heterogeneity. Furthermore, since $\text{CD}4^{+}$ cells have been implicated in the development of tobacco-related illnesses, such as asthma, they represent an ideal tissue to evaluate in the context of tobacco smoke exposure ([@c2]; [@c42]; [@c43]). Also, a novel aspect of the current study was its focus on Hispanic white individuals, a group that has been largely understudied in this context. An additional strength of our study was the matched design. In addition to focusing on Hispanic white participants to reduce potential confounding by race or ethnicity, we matched on several important confounders, including maternal age, gestational age, maternal diabetes status, and maternal BMI, to try to isolate the effects of exposure to maternal smoking *in utero* on the newborn methylome. Another major strength of our study was the inclusion of replication studies that also profiled DNA methylation in $\text{CD}4^{+}$ cells, which confirmed four regions and 33 CpGs that were identified as differentially methylated in MACHS. Finally, since MACHS was designed to identify early-life risk factors for adverse outcomes in childhood, regions found to be differentially methylated by maternal tobacco smoke exposure in the current study can be examined in relation to respiratory and other health outcomes in future studies.

Conclusions {#s5}
===========

Our findings contribute to growing evidence that exposure to maternal smoking *in utero* alters DNA methylation patterns in newborns, and present the first genome-wide description of the impact of maternal tobacco smoke exposure during pregnancy on the cord blood $\text{CD}4^{+}$ DNA methylome. In particular, our results suggest that maternal tobacco smoke exposure during pregnancy alters DNA methylation levels within coding regions and in important regulatory regions, such as enhancers, which have been largely uninvestigated. Although we used a WGBS pipeline that performs well on low-coverage data, our results should be interpreted with some caution, as it is still possible that the low-coverage of the data contributed to false positives. Nevertheless, we observed that a subset of results that could be queried replicated in several external study populations. For example, four of the nine DMRs identified in MACHS that could be examined in a study of adult $\text{CD}4^{+}$ cells were confirmed, and one differentially methylated CpG, located in the promoter region of *SLC7A8*, was validated in two different studies of $\text{CD}4^{+}$ cells (one conducted in newborns and the other in adults), which suggests that these loci are sensitive to tobacco smoke exposure in $\text{CD}4^{+}$ cells, and that these effects may span different life stages.
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